Thyrocare Technologies Schedules Board Meeting and Earnings Call on May 7, 2026
Thyrocare Technologies Limited has announced a board meeting and earnings conference call scheduled for May 7, 2026, to review audited financial results for Q4 and FY ended March 31, 2026. The conference call at 5:30 PM IST will feature comprehensive participation from senior management including Chairman Rahul Guha, CCO Rajdeep Panwar, COO Dr. Rameshinha, CFO Vikram Gupta, and Manager Strategy & Investor Relations Preet Joshi. The company has provided detailed dial-in arrangements with universal access numbers and webcast facilities for analysts and investors.
*this image is generated using AI for illustrative purposes only.
Thyrocare Technologies Limited has formally notified stock exchanges about an upcoming board meeting scheduled to review its annual financial performance and consider shareholder returns, along with hosting an earnings conference call for analysts and investors.
Board Meeting and Conference Call Details
The diagnostic services company has scheduled a board of directors meeting for Thursday, May 7, 2026, as per the regulatory intimation filed with both the National Stock Exchange of India Limited and BSE Limited on April 29, 2026. Additionally, the company will host an earnings conference call on the same day at 5:30 PM IST to discuss the audited financial results.
| Meeting Details: | Information |
|---|---|
| Date: | May 7, 2026 |
| Day: | Thursday |
| Board Meeting Agenda: | Audited Financial Results Approval |
| Conference Call Time: | 5:30 PM IST |
| Reporting Period: | Q4 and FY ended March 31, 2026 |
| Dividend Consideration: | Final Dividend Recommendation |
Key Agenda Items
The board meeting will focus on two primary matters. First, directors will consider and approve the audited standalone and consolidated financial results for both the quarter and financial year ended March 31, 2026. Second, the board will deliberate on recommending a final dividend for the financial year 2025-26, though the company has indicated this remains subject to board discretion.
Earnings Conference Call Arrangements
Pursuant to Regulation 30 of the SEBI Listing Regulations, Thyrocare has arranged a conference call for analysts and investors to discuss the company's audited financial results. The call will be conducted by senior management including Chairman, MD & CEO Mr. Rahul Guha, CCO Mr. Rajdeep Panwar, COO Dr. Rameshinha, CFO Mr. Vikram Gupta, and Manager - Strategy & Investor Relations Mr. Preet Joshi.
| Conference Call Details: | Information |
|---|---|
| Universal Access Numbers: | +91 22 6280 1408, +91 22 7115 8296 |
| Registration Required: | Early registration available online |
| Webcast Available: | Yes, via dedicated webcast link |
| Key Speakers: | 5 senior management officials |
| Confirmation Number: | 6099720 |
| Event ID: | THY070526 |
Senior Management Participation
The earnings call will feature comprehensive participation from Thyrocare's leadership team. The discussion will be led by Chairman, MD & CEO Mr. Rahul Guha, supported by Chief Commercial Officer Mr. Rajdeep Panwar and Chief Operating Officer Dr. Rameshinha. Financial insights will be provided by CFO Mr. Vikram Gupta, while Mr. Preet Joshi, Manager - Strategy & Investor Relations, will facilitate investor interactions.
| Management Team: | Designation |
|---|---|
| Mr. Rahul Guha: | Chairman, MD & CEO |
| Mr. Rajdeep Panwar: | CCO |
| Dr. Rameshinha: | COO |
| Mr. Vikram Gupta: | CFO |
| Mr. Preet Joshi: | Manager - Strategy & Investor Relations |
Trading Window Restrictions
In accordance with regulatory requirements, Thyrocare Technologies has implemented trading window restrictions to prevent insider trading. The trading window closed on April 1, 2026, affecting all designated persons and their immediate relatives from dealing in the company's equity shares.
| Trading Window Status: | Details |
|---|---|
| Closure Date: | April 1, 2026 |
| Applicable Regulations: | SEBI Insider Trading Regulations 2015 |
| Affected Parties: | Designated Persons and Immediate Relatives |
| Reopening Timeline: | 48 hours after results declaration |
Regulatory Compliance
Both the board meeting intimation and conference call invitation have been filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Brijesh Kumar signed both notifications on April 29, 2026, ensuring proper regulatory disclosure to stock exchanges where the company's shares are listed.
Historical Stock Returns for Thyrocare Technologies
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.00% | +1.19% | +10.81% | -11.08% | +34.89% | +14.55% |
How might Thyrocare's Q4 FY2026 performance compare to industry peers given the evolving diagnostic services market dynamics?
What strategic initiatives could Thyrocare announce during the earnings call to strengthen its competitive position in the diagnostic sector?
Will the potential final dividend recommendation signal Thyrocare's confidence in sustaining cash flows amid healthcare sector challenges?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
